AMRX vs SLDB

Amneal Pharmaceuticals, Inc.

(AMRX) offers the better valuation at 62. 4x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amneal Pharmaceuticals, Inc.

(AMRX) delivered a total return of +163. 8%, compared to -90. 0% for Solid Biosciences Inc. (SLDB). Over 10 years, the gap is even starker: AMRX returned -56. 6% versus SLDB's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amneal Pharmaceuticals, Inc.

(AMRX) is the lower-risk stock at 1. 08β versus Solid Biosciences Inc. 's 2. 18β — meaning SLDB is approximately 101% more volatile than AMRX relative to the S&P 500. On balance sheet safety, Solid Biosciences Inc. (SLDB) carries a lower debt/equity ratio of 12% versus 13% for Amneal Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc.

grew EPS 157. 9% year-over-year, compared to 35. 0% for Solid Biosciences Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amneal Pharmaceuticals, Inc.

(AMRX) is the more profitable company, earning 2. 4% net margin versus 0. 0% for Solid Biosciences Inc. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLDB leads at 0. 0% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — AMRX leads at 36. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SLDB: 126.

3% to $16. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amneal Pharmaceuticals, Inc.

(AMRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08)). Solid Biosciences Inc. (SLDB) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMRX: -56. 6%, SLDB: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.